Fujifilm Diosynth Biotechnologies expansion to add cell and microbial capacity 

Fujifilm Diosynth Biotechnologies U.S.A. expects to complete a 32,000 square-foot expansion to add purification suites at its facility in North Carolina in mid 2021. (Fujifilm Diosynth Biotechnologies U.S.A.)

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects, a $55 million expansion of its manufacturing facility in North Carolina. 

The company says the nearly 32,000 square-foot expansion is for purification suites that will allow it to boost its cell culture manufacturing capacity by about 25% and microbial capacity by about 50%.

RELATED: Fujifilm adding $120M facility to its gene therapy operations in U.S.

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

"This expansion is a reflection of Fujifilm's continued commitment to grow its bio-CDMO business and FDB, to provide our clients with not only the skills but also the infrastructure that will nimbly deliver their products to the clinic and beyond," Martin Meeson, COO of Fujifilm Diosynth Biotechnologies, U.S.A. said in a statement

A spokeswoman said the company will decide whether it needs more workers for the expansion once the work is complete in mid-2021. 

The Japanese CDMO in November also announced plans for a $120 million addition to its facilities in College Station, Texas. That project is expected to add 75 to 100 more scientists when the first phase is ready in 2021.

Last fall, the company also completed an $890 million deal to buy a biologics plant in Denmark from Biogen, taking on 800 employees. Fujifilm will manufacture Biogen’s multiple sclerosis drug Tysabri for the Cambridge, Massachusetts-based biotech.

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.